Jay Michael Balagtas, MD

Clinical Associate Professor

Profile Video

“I value the bonds I form not only with the patient but with the family as a whole.”

My philosophy has always been to seek out the best possible medical therapies for a patient's disease. Even in cases where we can't provide a definitive cure, we can still assist the family and patient in other ways. I let parents know that my care team and I will walk the whole way with them.

My patients are very inspiring to me. No matter how sick they are, they always put a smile on my face. Even though I am a pediatrician, I value the bonds I form not only with the patient but with the family as a whole. My care team and I always consider the needs of the entire family when we are designing treatment approaches and actively seek ways to reduce the burden on a family caring for a chronically ill child.

Specialties

Hematology-Oncology

Work and Education

Professional Education

New York Medical College Registrar, Valhalla, NY, 5/31/1998

Residency

United States Naval Medical Center San Diego Pediatric Residency, San Diego, CA, 06/30/2003

Fellowship

Stanford University Pediatric Hematology Oncology Fellowship, Palo Alto, CA, 6/30/2009

Board Certifications

Pediatric Hematology-Oncology, American Board of Pediatrics

View my Stanford Medicine academic profile

Services

Leukemia & Lymphoma

Oncology

Conditions Treated

Pediatric Leukemia

Pediatric Lymphoma

All Publications

A challenging case of recurrent idiopathic hemophagocytic lymphohistiocytosis (HLH) initially presenting in an infant with Pneumocystis jirovecii pneumonia Solomon, B., Balagtas, J., Chien, M., Pooni, R., Balboni, I., Weinacht, K., Gernez, Y. SPRINGER/PLENUM PUBLISHERS. 2021: S55

View details for Web of Science ID 000639851600094

P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs). Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F. D., Tran, B., Jeffery, M., Mazhar, D., Huddart, R. A., Walpole, E., Stevanovic, A., Wyld, D., Hanning, F. J., Wheater, M., Balagtas, J. R., Troon, S., Birtle, A., White, J. D., Grimison, P. S., Australian New Zealand Urogenital LIPPINCOTT WILLIAMS & WILKINS. 2021

View details for DOI 10.1200/JCO.2021.39.6_suppl.TPS390

View details for Web of Science ID 000636801500039

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs) Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F., Tran, B., Jeffery, M., Mazhar, D., Huddart, R., Walpole, E., Stevanovic, A. G., Wyld, D., Hanning, F. J., Wheater, M., Balagtas, J. M., Troon, S., Birtle, A., White, J., Grimison, P. S. WILEY. 2020: 205-206

View details for Web of Science ID 000790145400326

The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH JOURNAL OF THROMBOSIS AND HAEMOSTASIS Tullius, B. P., Athale, U., Van Ommen, C. H., Chan, A. C., Palumbo, J. S., Balagtas, J. S., Subcomm Hemostasis & Malignan, Subcomm Pediat Neonatal Throm 2018; 16 (1): 17580

View details for DOI 10.1111/jth.13895

View details for Web of Science ID 000419402000023

View details for PubMedID 29178421

Rate of abnormal vaginal bleeding and contraception counseling in women undergoing chemotherapy JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY Cutler, K. E., Creinin, M. D., Balagtas, J. S., Hou, M. Y. 2016; 14 (8): 33741

View details for DOI 10.12788/jcso.0290

View details for Web of Science ID 000398367400004

Subcutaneous Panniculitis-Like T-Cell Lymphoma: Pediatric Case Series Demonstrating Heterogeneous Presentation and Option for Watchful Waiting PEDIATRIC BLOOD & CANCER Johnston, E. E., LeBlanc, R. E., Kim, J., Chung, J., Balagtas, J., Kim, Y. H., Link, M. P. 2015; 62 (11): 2025-2028

Abstract

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and primary cutaneous gamma delta T-cell lymphoma (PCGD-TCL) were initially both classified as subcutaneous panniculitis-like T-cell lymphoma. In 2008, SPTCL with alpha-beta T-cell receptor subtype was separated from primary cutaneous gamma delta T-cell lymphomas (PCGD-TCL). We report four pediatric cases that demonstrate the heterogeneity of each disease and show that PCGD-TCL in children can have an indolent course, whereas SPTCL can behave aggressively. Three patients had spontaneous, durable remissions without treatment, whereas the one patient with disease progression was treated successfully. Watchful waiting may thus be appropriate for initial management of children.

View details for DOI 10.1002/pbc.25626

View details for PubMedID 26146844

Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS genetics Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J., Sweeney, R. T., Lai, E., Del Vecchio, C. A., Forster, A. D., Clarke, N., Montgomery, K. D., Zhu, S., Wong, A. J., van de Rijn, M., West, R. B., Pollack, J. R. 2013; 9 (4)

View details for DOI 10.1371/journal.pgen.1003464

View details for PubMedID 23637631

Therapeutic Complications in a Patient With High-Risk Acute Lymphoblastic Leukemia and Undiagnosed Hereditary Hemochromatosis PEDIATRIC BLOOD & CANCER Balagtas, J. M., Dahl, G. V. 2012; 58 (1): 101-103

Abstract

Hereditary hemochromatosis (HH) is an autosomal-recessive disorder of iron metabolism that most commonly manifests in the fourth or fifth decade of life. Here, we describe a 14-year-old male who presented with high-risk acute lymphoblastic leukemia and previously undiagnosed HH. His treatment course was remarkable for significant therapeutic complications, including iron overload, hepatic failure, cardiac dysfunction, and death. Postmortem testing revealed homozygosity for the C282Y mutation, confirming the diagnosis of HH. Since HH mutations occur commonly in select populations, screening patients with leukemia for HH may better inform treatment decisions regarding chemotherapy, transfusions, and/or iron chelation therapy.

View details for DOI 10.1002/pbc.22829

View details for Web of Science ID 000297641300020

View details for PubMedID 22076832

Liposomal amphotericin B associated with severe hyperphosphatemia PEDIATRIC INFECTIOUS DISEASE JOURNAL Sutherland, S. M., Hong, D. K., Balagtas, J., Gutierrez, K., Dvorak, C. C., Sarwal, M. 2008; 27 (1): 77-79

Abstract

We report 4 patients who developed hyperphosphatemia while receiving liposomal amphotericin B to treat an invasive fungal infection. Resolution of the hyperphosphatemia occurred after transition to amphotericin B lipid complex. This phenomenon may occur more commonly in patients with mild to moderate renal insufficiency.

View details for DOI 10.1097/INF.0b013e31815922a3

View details for PubMedID 18162947